Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche’s navify® Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses directly from navify® Digital Pathology platform.
Stockholm - Sweden, Sept. 09, 2024 (GLOBE NEWSWIRE) --
| Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche’s navify® Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses directly from navify® Digital Pathology platform. Stratipath Breast is the first EU regulatory-compliant solution for risk stratification of breast cancer using AI-based precision diagnostics. This deep learning-based solution analyses digitised haematoxylin and eosin-stained histopathology images of breast cancer tissue to enable the identification of patients with increased risk of disease progression, thus providing novel decision support for clinicians in the diagnostic evaluation of breast cancer. In contrast to conventional molecular tests, AI-based risk profiling offers shorter turnaround times for results, delivers new insights at the point of diagnosis, and substantially reduces the reliance on expensive molecular testing. As a result, Stratipath Breast provides broader accessibility and benefits for a greater number of breast cancer patients. "Stratipath Breast represents a significant advancement by offering a faster and more cost-effective alternative to traditional molecular assays. By integrating with Roche’s navify® Digital Pathology enterprise software, a large number of pathology labs globally now gain rapid access to AI-based prognostic insights, all while streamlining laboratory processes and minimising costs." says Fredrik Wetterhall, CEO and co-founder of Stratipath. This collaboration between Stratipath and Roche represents a significant step forward in breast cancer diagnostics. By harnessing the power of artificial intelligence and digital pathology, the two organisations are committed to improving the lives of breast cancer patients worldwide. |
||
|
Lars Lengquist Stratipath +46 709574782 lars.lengquist.press@stratipath.com |
-
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision DiagnosticsStratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche2024-09-09
-
VistaJet Connects China-Africa Business Ties, Propelling Cross-Continental CommerceVistaJet Connects China-Africa Business Ties, Propelling Cross-Continental Commerce Link for high resolution images. Image source: CCTV N2024-09-09
-
维思达公务机联系中国和非洲商务，推动中非商业发展维思达公务机联系中国和非洲商务，推动中非商业发展 高清图片可于此下载 维思达公务机_中非合作论坛 维思达公务机为一众商业领袖、国家元首和政府提供专机服2024-09-09
-
定义AI Agent四大核心能力，荣耀IFA剧透端侧AI创新进展继IFA首日荣耀Magic V3及Magic系列多品类旗舰级产品海外发布，为全球消费者带来多项软硬件结合、端云协同的AI创新体验，引发业界轰动之后，9月6日，荣耀CEO赵明在20242024-09-09
-
Meta做不到的，这家创业公司做到了Gyges Labs即将在光博会展出全球首款隐显眼镜解决方案。“显示，但不显露”成智能眼镜新标准。 对于一款智能眼镜来说，如果你想要舒适地全天候佩戴，你可能会想到Meta2024-09-09